Phase 2 Readout
ZBIO: Phase 2 Readout: obexelimab
June 30, 2026 · obexelimab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 30, 2026
- Company
- Zenas BioPharma, Inc. (ZBIO)
- Drug
- obexelimab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Readout~quarter
Phase 2 Readout: obexelimab
- Company
- Zenas BioPharma, Inc. (ZBIO)
- Drug
- obexelimab
- Indication
- Systemic Lupus Erythematosus